OOIR: Observatory of International Research

Papers

(The TQCC of Blood Reviews is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-10-01 to 2025-10-01.)

Article	Citations
Pitfalls in laboratory monitoring of treatment in people with Haemophilia	133
Editorial Board	133
Radiation and leukaemia: Which leukaemias and what doses?	90
Clinical burden of hemophilia in older adults: Beyond bleeding risk	61
Practical guidance on the prevention and management of infection in multiple myeloma patients: A case-based approach	60
Transplant-acquired allergy in HCT-recipients: Reference for clinical management	58
Not all LGL leukemias are created equal	55
Thalassaemia in China	52
Expanding post-transplant cyclophosphamide to matched unrelated donor transplants and beyond	50
The recipe for TACO: A narrative review on the pathophysiology and potential mitigation strategies of transfusion-associated circulatory overload	48
Beyond current treatment of Fanconi Anemia: What do advances in cell and gene-based approaches offer?	45
Artificial intelligence in sickle disease	45
Advances in the critical care management for patients with hematological malignancies	45
Breaking down frailty: Assessing vulnerability in acute myeloid leukemia	44
Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma	44
The landscape of immune monitoring in CAR-T cell therapy: A comprehensive review and survey study by the Cellular Therapy and Immunobiology Working Party of the EBMT	42
Targeting the neonatal Fc receptor (FcRn) in hematologic conditions with a focus on warm autoimmune hemolytic anemia	40
BTK inhibitors resistance in B cell malignancies: Mechanisms and potential therapeutic strategies	40
Failure of CAR-T cell therapy in relapsed and refractory large cell lymphoma and multiple myeloma: An urgent unmet need	37
Addressing the challenges of accelerated and blast phase myeloproliferative neoplasms in 2022 and beyond	37
Thrombotic events associated with immune checkpoint inhibitors and novel antithrombotic strategies to mitigate bleeding risk	37
Corrigendum to “Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme” [Blood Rev. 2023 Sep:61:101103]	37
Management of infection in PNH patients treated with eculizumab or other complement inhibitors: Unmet clinical needs	35
Chasing leukemia differentiation through induction therapy, relapse and transplantation	34
Gut microbiome composition and dysbiosis in immune thrombocytopenia: A review of literature	33

Harnessing multi-source data for individualized care in Hodgkin Lymphoma	33
The acute pain crisis in sickle cell disease: What can be done to improve outcomes?	33
Old tests and new paradigms: How to interpret iron studies and related biomarkers for the diagnosis of iron deficiency in adults	32
CHIPing away the progression potential of CHIP: A new reality in the making	32
Post-transplantation cyclophosphamide as GVHD prophylaxis in allogenic hematopoietic stem cell transplantation: Recent advances and modification	31
Gut dysbiosis, endotoxemia and clotting activation: A dangerous trio for portal vein thrombosis in cirrhosis	30
Endothelial cells: major players in acute myeloid leukaemia	30
Preservation of fertility in female patients with hematologic diseases	29
Richter's transformation: Transforming the clinical landscape	29
Metabolomics in sickle cell disease: Current knowledge and gaps – A scoping review	27
A new frontier in Fanconi anemia: From DNA repair to ribosome biogenesis	26
Down syndrome and leukemia: An insight into the disease biology and current treatment options	26
Current challenges in conditioning regimens for MDS transplantation	26
Factor B inhibitor iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria	26
Prevention and management of infectious complications in patients with chronic lymphocytic leukemia (CLL) treated with BTK and BCL-2 inhibitors, focus on current guidelines	26
Addressing the surge of infections by multidrug-resistant Enterobacterales in hematopoietic cell transplantation	25
Beyond the blood: A practical guide to thalassemia care in the emergency department	25
Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?	25
State-of-the-art review on AL amyloidosis in Western Countries: Epidemiology, health economics, risk assessment and therapeutic management of a rare disease	24
The mythological chimera and new era of relapse prediction post-transplant	23
Current state and next-generation CAR-T cells in multiple myeloma	22
Complementary and alternative medicine for children with sickle cell disease: A systematic review	22
ABCs of ADCs in management of relapsed/refractory diffuse large B-cell lymphoma	21
Optimizing high dose melphalan	21
Advances in the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia	21
Management of relapsed refractory multiple myeloma: Evidence-based guide to community oncologists	21
Αlpha-thalassemia: A practical overview	21
Navigating acute myeloid leukemia towards better outcomes: Treatment pathways and challenges for patients ineligible for intensive chemotherapy	21
Targeting health-related quality of life in patients with myelodysplastic syndromes – Current knowledge and lessons to be learned	20
Improving assessment and management of pain in hemophilia: an Italian Delphi consensus statement	20
Philadelphia chromosome-negative myeloproliferative neoplasms in younger adults: A critical discussion of unmet medical needs, with a focus on pregnancy	19
The role of preoperative transfusion in sickle cell disease, a systematic review and meta-analysis	19
Access to CAR T-cell therapy: Focus on diversity, equity and inclusion	19
Paroxysmal nocturnal hemoglobinuria: Review of the patient experience and treatment landscape	19
The critical role of platelets in venous thromboembolism: Pathogenesis, clinical status, and emerging therapeutic strategies	18
Biologic therapies for hypereosinophilic disorders: From tyrosine kinase inhibitors to monoclonal antibodies. Towards an increasingly customized management?	17
Bridging the evidence-to-practice gap: Advancing neonatal blood transfusion. A narrative review of recent guidelines	17
Putting function back in dysfunction: Endothelial diseases and current therapies in hematopoietic stem cell transplantation and cellular therapies	17
A new era in oxygen therapeutics? From perfluorocarbon systems to haemoglobin-based oxygen carriers	16
Innovations in red blood cell preservation	16
Ven the dose matters: Venetoclax dosing in the frontline treatment of AML	16
Quality of life, mood disorders, and cognitive impairment in adults with β-thalassemia	16
Androgen use in bone marrow failures and myeloid neoplasms: Mechanisms of action and a systematic review of clinical data	16
Diagnosis, therapeutic advances, and key recommendations for the management of factor X deficiency	16
How do we improve the translation of new evidence into the practice of hematopoietic cell transplantation and cellular therapy?	15
Perspective – The case for zero bleeds and drug bioequivalence in the treatment of congenital hemophilia A in 2021	15
Blasts in context: the impact of the immune environment on acute myeloid leukemia prognosis and treatment	15
The use of bone-modifying agents in multiple myeloma	15
A personalized, organ-based approach to the treatment of chronic steroid-refractory graft-versus-host disease	15